Strategic Leadership in aTENSION.life
Dr. Werner Lanthaler, a prominent figure in the life sciences industry, has been appointed as the Chairman of the Supervisory Board at aTENSION.life. His vast experience as the Founder and CEO of Wlanholding GmbH positions him to lead aTENSION.life into its next phase of growth. The company specializes in high-tech diagnostics aimed at transforming hypertension care.
Investment and Growth Potential
A recent financing round raised USD 3 million, with Wlanholding leading the investment and support from other key players, eQventure and VP Venture Partners. This financial boost is a significant milestone for aTENSION.life, providing the necessary resources to further develop its innovative diagnostics solutions.
Pioneering ALDO+ Technology
aTENSION.life's proprietary technology platform, ALDO+, is at the forefront of advancing diagnostics for hypertension. The platform focuses on making sophisticated mass spectrometry-based diagnostics readily available to patients suffering from uncontrolled hypertension.
Market Impact and Product Launch
ALDO+PA, the company's premiere product, specifically screens for primary aldosteronism—an often overlooked condition that affects a substantial percentage of individuals with high blood pressure. Despite the critical need for accurate diagnosis, many patients remain undiagnosed.
Vision for Better Healthcare
Dr. Lanthaler expressed his commitment to improving hypertension management, stating, "Every hypertension patient deserves an early and precise diagnosis leading to a targeted treatment. This funding brings us one step closer to making clinical mass spectrometry diagnostics widely available." This vision emphasizes the importance of early diagnosis and tailored treatments to enhance patient outcomes.
Expanding Horizons
Currently, the ALDO+PA test is available in select locations through partnerships, with plans to expand operations across key European markets. The company aims for a broader rollout across DACH markets by 2026, with customers already beginning to use the technology in multiple countries, enhancing access to critical healthcare solutions.
Challenges in Hypertension Care
With around 1.3 billion people affected by hypertension globally, underdiagnosis of certain subtypes remains a significant issue. aTENSION.life’s innovative solutions aim to alleviate this challenge, ensuring that more patients receive the necessary treatment.
Leadership Team and Future Directions
Under the guidance of Dr. Lanthaler, aTENSION.life has established a dynamic management team, including CEO Bernhard Klemen, CSO Marko Poglitsch, and CBO Katharina Wieser. Together, they are focused on steering the company towards realizing its ambitious goals in the healthcare landscape.
About Wlanholding GmbH
Wlanholding GmbH operates as a Family Office committed to investing in innovative life science and technology-driven sustainability initiatives. Dr. Lanthaler, a recognized leader in this field, is dedicated to fostering entrepreneurs and management teams in order to innovate and grow businesses with meaningful impact.
About aTENSION.life
aTENSION.life focuses on advancing hypertension care through accessible and efficient diagnostics. The innovative ALDO+ platform is set to redefine precision in diagnosing hypertension, making targeted therapies simpler and more effective with just one blood sample.
Frequently Asked Questions
What is Dr. Werner Lanthaler's role at aTENSION.life?
Dr. Werner Lanthaler serves as the Chairman of the Supervisory Board, guiding the company's strategic direction and innovation efforts.
What is the ALDO+ technology platform?
The ALDO+ platform provides advanced diagnostics for hypertension, focusing on precision in identifying critical conditions like primary aldosteronism.
What is the significance of the recent investment?
The USD 3 million investment from Wlanholding and other partners will accelerate product development and expand market reach for aTENSION.life.
Who are the members of the management team at aTENSION.life?
The management team includes CEO Bernhard Klemen, CSO Marko Poglitsch, and CBO Katharina Wieser, each playing pivotal roles in driving the company's vision.
How does aTENSION.life plan to address hypertension treatment gaps?
By providing innovative diagnostics tools like the ALDO+PA test, aTENSION.life aims to tackle the underdiagnosis of hypertension subtypes, ensuring better treatment accessibility for patients globally.
